Wendell David Associates Inc. Purchases 225 Shares of Novo Nordisk A/S (NYSE:NVO)

Wendell David Associates Inc. grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 76,847 shares of the company’s stock after purchasing an additional 225 shares during the quarter. Wendell David Associates Inc.’s holdings in Novo Nordisk A/S were worth $6,610,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Raymond James & Associates raised its position in shares of Novo Nordisk A/S by 1.0% during the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock valued at $419,939,000 after buying an additional 36,223 shares in the last quarter. Natixis Advisors LLC increased its position in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares during the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC lifted its stake in Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after purchasing an additional 1,593,303 shares during the last quarter. Finally, LPL Financial LLC lifted its stake in shares of Novo Nordisk A/S by 3.6% during the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock worth $162,266,000 after acquiring an additional 47,496 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.5 %

Novo Nordisk A/S stock opened at $80.59 on Thursday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock’s 50 day simple moving average is $96.63 and its two-hundred day simple moving average is $116.04. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The firm has a market cap of $361.65 billion, a PE ratio of 26.08, a P/E/G ratio of 0.89 and a beta of 0.45.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.